Investment summary

The grant of two new patents broadens Phylogica’s core IP portfolio and strengthens its potential to exploit its Phylomer peptide drug discovery platform. Phylogica’s strategy is to become a preferred drug discovery partner for large pharma. Phylogica’s investment case continues to rest on its ability to monetise its proprietary discovery platform, by both achieving milestones under its four existing collaborations and securing additional deals. Active discussions are ongoing for new discovery alliances and at least one, if not two, are targeted by end-June 2012.

Last updated on 11/05/2012

Industry outlook

Peptides have some advantages of small molecules (stability, formulation flexibility and COGS) and the binding specificity of antibodies, but their key benefit is the ability to address intractable intracellular targets. Phylomer libraries are a source of novel peptide drug leads; which due to their diversity yield better quality and quantity hits vs random peptide libraries.

Last updated on 23/04/2012